Talquetamab

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2].

Product Specifications

CAS Number

[2226212-40-2]

Product Name Alternative

JNJ-64407564

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/talquetamab.html

Purity

98.52

Solubility

10 mM in DMSO

Smiles

[Talquetamab]

Molecular Weight

(144.58 kDa)

References & Citations

[1]Christie P M Verkleij, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5 (8) :2196-2215.|[2]Kodandaram Pillarisetti, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135 (15) :1232-1243.